Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

Annals of Oncology

Volumn 13, Issue 7, 2002, Pages 1116-1119

  Alexanian, R ^a   Weber, D ^a   Giralt, S ^a   Delasalle, K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Thalidomide

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; PARAPROTEIN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ANKLE EDEMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOSE RESPONSE; DRY SKIN; FATIGUE; FEMALE; HUMAN; INDIGESTION; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PARESTHESIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RASH; TREMOR; TUMOR VOLUME; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MAXIMUM TOLERATED DOSE; METHODOLOGY; MIDDLE AGED; MORTALITY; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPARATIVE STUDY; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGE; MULTIPLE MYELOMA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035990841     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf188     Document Type: Article

References (14)

1. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated multiple myeloma
2. Early myeloablative therapy for multiple myeloma
3. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma
4. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
5. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma
6. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
7. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients
8. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma
9. Antitumor activity of thalidomide in refractory multiple myeloma
10. Thalidomide for resistant and relapsing myeloma
11. Thalidomide with dexamethasone for resistant multiple myeloma
12. Thalidomide and dexamethasone combination for refractory multiple myeloma
13. Primary dexamethasone treatment of multiple myeloma
14. Myeloma protein kinetics following chemotherapy